Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935748 · ClinicalTrials.gov registry record · Phase 2
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
A Phase 2 study, sponsored by NiKang Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT05935748 is a Phase 2 study that was terminated before completion, run by NiKang Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT05935748, a Phase 2 study, was terminated before completion, sponsored by NiKang Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.
Interventions
- DRUG palbociclib
- DRUG NKT2152
- OTHER sasanlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05935748
The ClinicalTrials.gov registry entry for NCT05935748 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NiKang Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which palbociclib is the first listed.
NCT05935748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05935748 about?
NCT05935748 is a clinical study titled "Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)". The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear ce...
What is the current status of trial NCT05935748?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2023-07-28. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT05935748?
The interventions under investigation include: palbociclib (DRUG), NKT2152 (DRUG), sasanlimab (OTHER).
Who is sponsoring clinical trial NCT05935748?
This trial is sponsored by NiKang Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.